1. Home
  2. ECBK vs PEPG Comparison

ECBK vs PEPG Comparison

Compare ECBK & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ECB Bancorp Inc.

ECBK

ECB Bancorp Inc.

SELL

Current Price

$21.12

Market Cap

182.5M

Sector

Finance

ML Signal

SELL

Logo PepGen Inc.

PEPG

PepGen Inc.

SELL

Current Price

$2.52

Market Cap

179.4M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
ECBK
PEPG
Founded
1919
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
182.5M
179.4M
IPO Year
2022
2022

Fundamental Metrics

Financial Performance
Metric
ECBK
PEPG
Price
$21.12
$2.52
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
★ $10.19
AVG Volume (30 Days)
6.5K
★ 695.1K
Earning Date
10-26-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 95.83
25.61
EPS
★ 0.77
N/A
Revenue
★ $598,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$27.16
★ N/A
Revenue Growth
★ 3.64
N/A
52 Week Low
$14.83
$1.31
52 Week High
$21.78
$7.80

Technical Indicators

Market Signals
Indicator
ECBK
PEPG
Relative Strength Index (RSI) 52.55 46.25
Support Level $20.03 $1.60
Resistance Level $21.06 $2.62
Average True Range (ATR) 0.61 0.18
MACD 0.02 0.00
Stochastic Oscillator 67.82 40.67

Price Performance

Historical Comparison
ECBK
PEPG

About ECBK ECB Bancorp Inc.

ECB Bancorp Inc operates as a bank holding company. The firm, through its subsidiary, engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, multifamily real estate loans, construction and land loans, and home equity lines of credit.

About PEPG PepGen Inc.

PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.

Share on Social Networks: